CONNECT WITH US
HealthTech

HealthTech

Intuitive expands push into cardiac market with CE mark

MedTech Dive logo

Published on

Add as a preferred source on Google
Intuitive expands push into cardiac market with CE mark

After de-emphasizing heart surgery for decades due to limits with its earlier platforms, the surgical robot maker is eyeing the large market in cardiovascular disease treatment.

Cardiac surgery represents a large market opportunity, with cardiovascular diseases the leading cause of death worldwide. CFO Jamie Samath told investors on Intuitive’s second-quarter earnings call that cardiac procedures are among the company’s most anticipated long-term opportunities.

The heart surgery strategy comes as Intuitive experienced an unexpected slowdown in U.S. procedures growth in the second quarter.

Intuitive is also ramping up its cardiac initiative in the U.S. Earlier this year, the company revealed that da Vinci 5, its most advanced system, had received Food and Drug Administration clearance in nine heart procedures, including mitral and tricuspid valve repair, mitral valve replacement and left atrial appendage closure.

The design of da Vinci 5 enables surgeons to operate through small incisions without opening the patient’s breastbone.

The robot maker plans to offer new instruments for cardiac procedures and provide a dedicated infrastructure to support customers, said Dirk Barten, Intuitive’s commercial president for Europe.

“This clearance represents our firm commitment to bring back robotic-assisted minimally invasive cardiac procedures in Europe,” Barten said in a statement.

The company said it is also focused on clinical evidence generation and will partner with a limited number of European centers to establish reproducible cardiac surgery programs for scaling up.



Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.